Is Infigratinib launched in China?

Infigratinib/Infigratinib (Infigratinib) has not yet been launched in China. However, the marketing status of a drug may change over time, and the clinical research and drug approval processes may change in the future.

Infigratinib/Infigratinib is not currently on the market in China, and it is unlikely to be included in medical insurance. Patients cannot purchase it domestically and can only purchase it through overseas channels. Foreign infigratinib/Infigratinib only has the original drug, the only American original drug, and the price is as high as about 200,000.

Infitinib/Infigratinib is a targeted therapy drug mainly used to treat certain subtypes of cholangiocarcinoma (Cholangiocarcinoma), especially those with activated FGFR2 gene fusions or rearrangements. The drug's mechanism of action involves inhibiting the activity of the fibroblast growth factor receptor (FGFR), thereby slowing or stopping the growth and spread of cancer cells. Cholangiocarcinoma is a malignant tumor that originates from the epithelial cells of the bile duct, or biliary tract, and is often difficult to diagnose in its early stages and therefore difficult to treat. Infigratinib/Infigratinib represents a new treatment option that offers hope for some patients with cholangiocarcinoma.

If you or a loved one has cholangiocarcinoma or requires certain medications, it is recommended that you first consult with a local medical professional or oncologist. They can provide information about the latest treatment options and available medications. New drugs may be in clinical trials but not yet officially on the market. You can find out if there are any ongoing clinical trials to see if there is an opportunity to participate or get early access to the drug.

Please note that a drug's marketing status may be affected by a variety of factors, including the results of clinical trials, the drug regulatory approval process, and pharmaceutical company decisions. Therefore, the availability and marketing status of a drug may change over time. The best thing to do is to consult a medical professional and regularly check relevant authoritative information sources for the latest information about infigratinib or other treatments.